Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study

Quality of Life Clinical Trial

— WIN  

Official title:

Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study (Pilot WIN-study).

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01849523
• Other study ID #: Pilot WIN-2013
• Secondary ID: NL43834.042.13
• Status: Completed
• Phase: N/A
• Start date: October 2013
• Est. completion date: August 2014

Study information

• Verified date: May 2024
• Source: University Medical Center Groningen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background Physical as well as psychosocial complaints are frequently present in patients with a neuroendocrine tumor (NET). Adequate information is seen as an essential aspect of supportive care. The aim of the current study is to test the effectiveness of a web-based tailored information and support system targeting patients' information and care needs. Key features of this system are self-screening of physical and psychosocial problems, tailored education on reported problems and self-referral to professional health care.

Objective To detect whether a web-based tailored information and support system improves patients' perception and satisfaction of received information. The investigators hypothesize that after having received web-based tailored information and support patients feel more informed and are more satisfied with the received information than when receiving standard care.

Study design The present study is a randomized prospective longitudinal experimental multicenter pilot study. In this study, we want to examine the effect sizes on the perception and satisfaction by the patient of received information (primary objective) and secondary objectives after having used web-based tailored information and support. Eligible are newly diagnosed NET-patients (N=40) (diagnosed less than 3 months ago). Patients will be asked to fill out questionnaires at baseline and after 12 weeks, on socio-demographic features (only at baseline), internet use (only at baseline), health care use, patients' perception and satisfaction of received information, distress, quality of life and empowerment (only after 12 weeks).

Study population Patients diagnosed with a NET (any type of NET, any phase of disease) who are under treatment at the Department of Medical Oncology in the University Medical Center Groningen or Hospital Medisch Spectrum; twenty will be invited to participate in the study.

Intervention During 12 subsequent weeks, a personalized website (with a surname/password) will become available to patients in the experimental group beside the usual standard care. Key features of the website are self-screening, tailored patient education and self-referral. Self-screening will be performed by an online version of the Dutch Distress thermometer (DT) and Problem List (PL). Patients will receive automated feedback on their DT score immediately after test completion together with information regarding problems reported on the PL, options for (self)-help and possibilities for referral to professional care. Contact information will also be available to discuss questions, problems and/or referral needs. Patients may also request a telephone call.

Main study endpoint The primary endpoint is to detect an improvement in patients' perception and satisfaction of received information after having received web-based tailored information and support.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 2014
• Est. primary completion date: August 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult NET patients (aged = 18 years of age) with any tumor site and disease stage.

• Ability to comprehend Dutch (both reading and writing).

• Informed consent provided.

Exclusion Criteria:

• Estimated life expectancy less than 3 months.

• Patients with a second primary tumor for which active follow-up or treatment.

Related Conditions & MeSH terms

• Distress
• Neuroendocrine Tumor
• Neuroendocrine Tumors
• Quality of Life

Intervention

Behavioral:
• Web-based information and support

Locations

Country	Name	City	State
Netherlands	Medical Spectrum Twente	Enschede
Netherlands	University Medical Center Groningen	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	detect an improvement in perception and satisfaction of the received information	The primary objective is to detect an improvement in perception and satisfaction of the received information by NET-patients after having used the online tailored information and support system. We hypothesize that patients perceive to have received more information and are more satisfied with the received information after having used the web-based tailored information and support system.	14 weeks. This is the period a patient can use the website, thereafter a end-of study questionnaire will be filled out
Secondary	Distress level after receiving information	To test whether patients experience less distress after having received web-based tailored information and support.	14 weeks. This is the period a patient can use the website, thereafter a end-of study questionnaire will be filled out
Secondary	Quality of life	To test whether patients experience a higher quality of life after receiving web-based tailored information and support.	14 weeks. This is the period a patient can use the website, thereafter a end-of study questionnaire will be filled out
Secondary	Empowerment enhancement	To examine whether a web-based tailored information and support system enhances empowerment within the meaning of being better informed, feeling more confident in the relationship with their physician, improved acceptance of the illness, feeling more confident about the treatment and increased optimism and control over the future.	14 weeks. This is the period a patient can use the website, thereafter a end-of study questionnaire will be filled out